eXoZymes Inc Stock Price, News & Analysis

eXoZymes (NASDAQ:EXOZ) announced that CEO Michael Heltzen will present at the Spartan Capital Securities Second Annual Investor Conference on November 3, 2025 at the Marriott Marquis Hotel in New York City.

The 15-minute presentation is scheduled for 11:20–11:35 AM at Track 4 and will cover the company’s AI‑engineered, cell‑free biomanufacturing platform and its flagship small molecule product, NCT, aimed at metabolic and gut‑health markets.

eXoZymes (NASDAQ:EXOZ) announced that CEO Michael Heltzen will present at the ThinkEquity Annual Investor Conference on October 30, 2025 at the Mandarin Oriental Hotel in New York City.

The 30-minute presentation is scheduled for 8:00–8:30 AM in Lotus Suite East and will describe eXoZymes' AI-engineered enzyme platform—branded exozymes—which the company says enables cell-free, scalable biomanufacturing for natural products and potential pharmaceuticals. Management highlights a natural product called NCT that is reported to be showing promising results in improving metabolic health.

ThinkEquity expects over 750 institutional and high-net-worth investors and more than 85 selected companies to attend the conference.

eXoZymes (NASDAQ:EXOZ), a pioneer in AI-engineered enzymes for sustainable biomanufacturing, announced key leadership appointments to BioMADE Governance Committees. CCO Damien Perriman has been elected to the BioMADE Leadership Council, while VP of Development Dr. Paul Opgenorth joins the Technical Committee.

These appointments position eXoZymes as a thought leader in cell-free biomanufacturing, with both executives set to influence national priorities and technical roadmaps through BioMADE, a federally funded Manufacturing Innovation Institute. Dr. Opgenorth brings additional expertise from his role as PI in the NSF's CFIRE program and BioMADE 4.0 project.

eXoZymes (NASDAQ:EXOZ), a pioneer in AI-engineered enzymes, announced its Q2 2025 financial results and operational highlights. The company secured a significant role in a $9M NSF-funded initiative, receiving a $3M share to develop cell-free biomanufacturing solutions. The quarter saw increased operating expenses of $1.20M and a net loss of $2.36M.

Notable achievements include a breakthrough in gram-scale NCT production with 96% yield and 99% purity. The company ended Q2 with $6.99M in cash, sufficient to fund operations through Q1 2026. Management will discuss these results and future outlook in today's earnings call at 5:00 PM ET.

eXoZymes (NASDAQ:EXOZ), a company specializing in AI-engineered enzymes for sustainable feedstock transformation, has announced its upcoming Q2 2025 earnings webinar. The event will take place on Tuesday, August 12, 2025, at 5:00 PM ET.

CEO Michael Heltzen and management team members will discuss quarterly results, recent developments, ongoing initiatives, and future milestones. The presentation will include a Q&A session. Investors can pre-register for the webinar or access it through the company's investor relations website on the day of the event.

eXoZymes (NASDAQ:EXOZ) and its spinout NCTx have achieved a significant biomanufacturing breakthrough, producing 4 grams of N-trans-caffeoyltyramine (NCT) with over 99% purity and 96% yield using their AI-driven exozymes platform.

The project progressed from concept to gram-scale production in just 5 months, significantly faster than traditional synthetic biology approaches. NCT, naturally found in trace amounts in hemp seeds (less than 0.014%), has shown potential benefits for liver fat metabolism, gut barrier function, and mitochondrial activity.

The company plans to scale production 100X over the next six months and is preparing for GMP pilot scale production in 2026. The bioactive ingredients market represents a $216 billion opportunity with 7.6% CAGR globally. eXoZymes is actively seeking early access partners under material transfer agreements.

eXoZymes (NASDAQ:EXOZ) and its spinout NCTx have achieved a significant biomanufacturing breakthrough in producing N-trans-caffeoyltyramine (NCT), a bioactive compound. The company successfully went from concept to gram-scale production in just 5 months, achieving a 96% reaction yield.

This milestone addresses the challenge of sourcing NCT, which naturally occurs in trace amounts (less than 0.014%) in hemp seeds. The breakthrough enables commercial viability in the $216 billion functional food market, growing at 7.6% CAGR. NCT shows promise in supporting liver fat metabolism, gut barrier function, and mitochondrial activity, with preclinical studies demonstrating enhanced fat breakdown and potential NAFLD/MASLD treatment applications.

eXoZymes (NASDAQ:EXOZ) has been selected as a core industry partner in the $9.2 million NSF-funded Meta-PURE initiative, led by Georgia Tech. The company will receive a $3 million share of the total funding to develop a cell-free ATP-generating module that will serve as a power source for various chemical production processes.

As the key industrial partner, eXoZymes will focus on creating a standardized, plug-and-play cell-free power plant system that enables faster reaction times and greater product yields. The company will also develop a production module for santalene, a high-value fragrance compound used in aromatherapy and traditional medicine.

eXoZymes (NASDAQ:EXOZ), a company specializing in AI-engineered enzymes, was featured on the Grow Everything podcast discussing their innovative biomanufacturing platform. CEO Michael Heltzen highlighted how their exozymes technology enables sustainable chemical production outside living cells, offering advantages over traditional cell-based synthetic biology.

The company announced their first spinout, NCTx, which focuses on producing NCT, a rare small molecule with potential treatment applications for non-alcoholic fatty liver disease (NAFLD). eXoZymes is actively pursuing partnerships for co-development and licensing, with current projects including nutraceuticals, pharmaceuticals, and Sustainable Aviation Fuels backed by DoE and DoD funding.